Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism by Milger, Katrin et al.
© 2015 Milger et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of COPD 2015:10 891–897
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
891
C a s e  r e P O rt
open access to scientific and medical research
Open access Full text article
http://dx.doi.org/10.2147/COPD.S80173
Identification of a novel SERPINA-1 mutation 
causing alpha-1 antitrypsin deficiency in a patient 








1Department of Internal Medicine V, 
University of Munich, Comprehensive 
Pneumology Center, Member of the 
German Center for Lung research, 
2Institute of Laboratory Medicine, 
University of Munich, Munich, 
Germany
Abstract: Deficiency in the serine protease inhibitor, alpha-1 antitrypsin (AAT), is known to 
cause emphysema and liver disease. Other manifestations, including airway disease or skin dis-
orders, have also been described. A 44-year-old woman presented to our emergency department 
with dyspnea and respiratory insufficiency. She had never smoked, and had been diagnosed with 
COPD 9 years earlier. Three months previously, she had suffered a pulmonary embolism. Chest 
computed tomography scan revealed severe cystic bronchiectasis with destruction of the lung 
parenchyma. The sweat test was normal and there was no evidence of the cystic fibrosis transmem-
brane conductance regulator (CFTR) mutation. Capillary zone electrophoresis showed a decrease 
of alpha-1 globin band and AAT levels were below the quantification limit (,25 mg/dL). No S 
or Z mutation was identified, but sequencing analysis found a homozygous cytosine and adenine 
(CA) insertion in exon 2 of the SERPINA-1 gene, probably leading to a dysfunctional protein 
(PI Null/Null). This mutation has not been previously identified. The atypical presentation of the 
patient, with severe cystic bronchiectasis, highlights AAT deficiency as a differential diagnosis 
in bronchiectasis. Further, awareness should be raised regarding a possible increased risk of 
thromboembolism associated with AAT deficiency.
Keywords: alpha-1 antitrypsin deficiency, bronchiectasis, SERPINA-1 mutation, pulmonary 
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Introduction
Alpha-1 antitrypsin (AAT) is an antiprotease, produced mainly by hepatocytes, that 
opposes the activity of human neutrophil elastase and several other proteases, includ-
ing proteinase-3 and plasmin activator. Its normal plasma concentration is in the range 
of 120–200 mg/dL.1,2
AAT deficiency is an autosomal codominant disorder that predisposes to chronic 
obstructive pulmonary disease (COPD) and liver disease. A plasma concentration 
below 11 µM (50–80 mg/dL depending on the assay) is considered to represent a 
relevant deficiency. It is caused by inheritance of two severe deficiency alleles of the 
SERPINA-1 gene located on chromosome segment 14q31–32.3.2 Variants of AAT 
alleles are conventionally classified as normal, deficient, and null alleles.
Isoelectric focusing has been the classical gold standard for phenotyping AAT 
deficiency alleles. It separates protein variants based on their migration in an electro-
phoretic field at alkaline pH, and is used for classification. Normal variants belong 
to the M alleles of AAT, whereas the A–L variants run faster and N–Z variants run 
slower than the M band in an isoelectric field.2
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The most common deficiency mutation leading to very low 
serum AAT levels (ie, 10%–15% of the normal level) is the Z 
mutation (p.Glu366Lys), whereas the S mutation (p.Glu288Val) 
is associated with mildly reduced AAT levels (ie, 30%–40% of 
normal). Several rare null variants, named Q0, associated with 
trace amounts (,1%) of plasma AAT have been described, 
resulting from a broad range of molecular mechanisms. Frame-
shift or nonsense mutation leads to premature stop codons in 
SERPINA-1 with either unstable mRNA or truncated, unstable pro-
teins (eg, Q0
Granite Falls
).3 Other mechanisms include complete gene 
deletion (eg, Q0
Isola di Procida
)4 or splicing mutations (eg, Q0
Madrid
).5,6
Emphysema is due to a protease-antiprotease imbalance 
causing destruction of the alveolar wall. Liver disease is 
caused by hepatocyte injury due to intracellular accumulation 
of polymerized AAT molecules occurring only in certain 
mutations, eg, the Z allele.1,2
Early-onset “pure” panacinar emphysema is the classical 
respiratory disease manifestation in adulthood. However, 
other pulmonary manifestations, such as airway hyperreactiv-
ity, wheezing, chronic cough, and expectoration of sputum, 
have been described. Additionally, extrapulmonary disease 
manifestations have been recognized, such as necrotizing 
panniculitis and other skin diseases,7–9 as well as an increased 
risk for vasculitis10,11 and thromboembolism.7,12,13 We report a 
case of AAT deficiency presenting with severe bronchiectasis 
and absence of classical emphysema. Remarkably, the patient 
was homozygous for a novel mutation, ie, an insertion of 
cytosine and adenine (CA) in exon 2.
Case presentation
A 44-year-old woman of Turkish origin presented to the 
emergency department with severe dyspnea and inspiratory 
pleural chest pain that had developed over the previous 
few days. She had delivered healthy twins 6 weeks prior 
to presentation and had been diagnosed with a pulmonary 
embolism 3 months previously. She had never smoked. Her 
past medical history revealed a diagnosis of COPD that had 
been made 9 years earlier during her pregnancy with her 
first child, at which time she became symptomatic for the 
first time. There was no family history of respiratory or liver 
disease. She had no history of childhood asthma or allergies. 
Her current medication consisted of subcutaneous tinzaparin, 
a low molecular weight heparin, for pulmonary embolism, 
and inhaled tiotropium, formoterol, and budesonide.
Initial laboratory workup showed a leukocytosis of 
12.6 g/L (normal range 6–11 g/L), mildly elevated C-reactive 
protein of 2.6 (normal range ,0.5) and thrombocytosis of 
485 g/L (normal range 150–400 g/L). Differential white 
blood cells showed an eosinophilia of 7% (normal ,4%). 
Blood gas analysis showed severe respiratory insufficiency 
(paO
2
 54 mmHg, paCO
2
 38 mmHg).
A chest computed tomography scan revealed very severe 
bronchiectasis with large cysts and mucus plugging, pre-
dominantly in the lower lung segments, suggestive of cystic 
fibrosis (Figure 1). Additionally, ground glass opacities were 
noted in the upper lung segments and infiltrates in the right 
middle lobe. Marked emphysema was not present, and no 
residual thrombi were seen in the pulmonary arteries. Upon 
echocardiography, right and left heart function were normal 
and her brain natriuretic peptide level was normal.
Lung function analysis showed severe obstruction 
(forced expiratory volume in 1 second [FEV
1
] 1,06 L/43%, 
FEV
1
/vital capacity 47%) and moderate relative hyperin-
flation (residual volume 2.2 L/140%, total lung capacity 
4.37 L/99%). Sputum analysis revealed mucoid Pseudomo-
nas aeruginosa and Aspergillus fumigatus. Mycobacterial 
infection was excluded by repeated sputum analysis, includ-
ing polymerase chain reaction. An interferon-gamma release 
assay for tuberculosis antigen-specific T-cell response was 
negative. Bronchiectasis workup, including immunoglobu-
lin (Ig)A, IgM, IgG, and subclasses, was normal. Total IgE 
levels were increased to 584 IU/mL (normal ,100 IU/mL) 
and specific IgG and IgE were high for A. fumigatus (IgG 
106 mgA/I; low range ,14 mgA/I, intermediate range 14–39 
mgA/I; high range .39 mgA/I; IgE 46 IU/mL, FEIA class 4), 
indicative of possible allergic bronchopulmonary aspergil-
losis (ABPA). Prick testing against common environmental 
antigens, such as pollen, house dust mite, and animal hair, 
was negative. An antinuclear antibody titer of 1:100 was 
noted, but extractable nuclear antigen screening (RNP/Sm, 
Sm, SS-A, SS-B, Scl70, CentB, Ho-1, Rib-P) was unremark-
able. Antineutrophil cytoplasmic antibody (ANCA) testing 
was negative. A thrombophilia screen, including factor V 
Leiden, prothrombin gene mutation, antithrombin 3, proteins 
C and S, and lupus anticoagulant had been performed at the 
time of diagnosis and had revealed no abnormalities.
Sweat chloride testing was normal (,25 mM) and no 
CFTR gene mutation was found. Capillary zone electropho-
resis indicated a marked decrease in alpha-1 globin band 
0.18 g/dL, 2.6% (Figure 2). The AAT level in serum was 
below 25 mg/dL (measured by the Cobas C702 nephelom-
etry kit, Roche, Basel, Switzerland; quantification range 
25–600 mg/dL, detection limit 10 mg/dL).
Upon genetic testing, no S or Z mutations were found in 
the sequencing of exon 3 or exon 5 of the SERPINA-1 gene. 

















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Novel SERPINA-1 mutation associated with severe bronchiectasis
gene revealed a homozygous CA insertion in exon 2, leading 
to a frame shift starting at codon 73. This mutation prob-
ably leads to a dysfunctional truncated protein lacking the 
reactive center loop (Figure 3). There was no suggestion 
of liver disease on sonography and liver enzymes (alanine 
transaminase, aspartate transaminase, gamma-glutamyl 
transpeptidase, alkaline phosphatase) were normal. There 
was no apparent skin disease.
The patient was treated with oxygen therapy, oral cipro-
floxacin, and inhaled colistin twice daily for P. aeruginosa 
infection. Later, itraconazole and prednisolone were added 
for treatment of probable ABPA.
Discussion
AAT deficiency is a clinically underdiagnosed genetic dis-
ease classically presenting with panacinar pulmonary emphy-
sema. Although less common, an association between AAT 
deficiency and bronchiectasis has also been described,14,15 and 
testing for AAT deficiency is recommended in the workup 
of bronchiectasis.2
Mechanistically, the protease-antiprotease imbalance 
responsible for the development of emphysema is also 
thought to cause bronchiectasis. Unopposed human neutro-
phil elastase from polymorphonuclear influx in the airways 
leads to injury of bronchial connective tissue, since normal 
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microbial and native airway cellular interaction may be 
amplified.16
It has been suggested that AAT deficiency may be associ-
ated with an increased risk of venous thromboembolism.7,12,13 
Our patient experienced thromboembolism during pregnancy, 
which in itself is a sufficiently strong risk factor. A larger 
study would be necessary to establish if such a correlation 
can be confirmed.
There are two possible mechanisms for increased thrombo-
philia in AAT deficiency. An unopposed proteolytic activity of 
plasminogen activator could cause activation of the coagula-
tion cascade. Additionally, unopposed proteinase-3 activity 
may damage and/or activate endothelial cells, resulting in a 
prothrombotic state. An increased risk for ANCA-associated 
vasculitis (Wegener’s granulomatosis) has been established,10,11 
but signs of vasculitis or ANCAs were not found in our patient. 
AAT plays an important role as an inhibitor of proteinase-3, a 
neutrophil elastase-like serine protease located in the primary 
granules of the neutrophil. AAT deficiency could increase 
unchecked proteinase-3, which in turn exerts a potent tissue-
destructive capacity, triggering an autoimmune response by 
allowing increased extracellular exposure to proteinase-3.10
Diagnosis of ABPA was probable in our patient because 
she had A. fumigatus in sputum, increased total IgE, and 
increased specific IgE and IgG titers, as well as exacerbation 
of her disease with a pulmonary infiltrate. ABPA classically 
occurs in patients with asthma or cystic fibrosis, but cases 
in patients with COPD or non-cystic fibrosis bronchiectasis 
have also been described. APBA may also be the cause of 
bronchiectasis in patients with asthma. Our patient did not 
have a history of allergies or asthma. Hence, we assume 
ABPA might have aggravated the disease, but was not the 
primary cause of bronchiectasis.
Via sequencing analysis, a novel SERPINA-1 mutation 
was identified, consisting of a homozygous CA insertion in 
the exon 2 that leads to a frameshift mutation with a prema-
ture stop codon. The resulting protein is truncated at one-third 
of the amino acid sequence and lacks the reactive center loop 
(Figure 3). Hence, there is no antiproteolytic activity, and 
a null phenotype (PI Q0/Q0) must be assumed. Classically, 
different AAT alleles have been characterized by phenotyp-
ing using isoelectric focusing, and this method is considered 
the gold standard for phenotypic analysis. However, this 
method is reserved for experienced reference laboratories. 
Moreover, it may miss relevant mutations because mutated 
proteins may exhibit similar migration characteristics as the 




 alleles, or in the event 
of heterozygosity for the M allele and a null allele.17 Since 
genotyping by whole gene sequencing is now widely avail-
able, we used a combination of AAT quantification in plasma 
by nephelometry and whole gene sequencing as suggested 
by a current diagnostic algorithm.18 A phenotypic analysis 
of the mutant protein by isoelectric focusing as well as RNA 
expression analysis by reverse transcription polymerase chain 
reaction would help to characterize the novel mutation in 
more detail, but was not available at our center. Generally, 
null mutations are considered to be very rare; however, 
their prevalence may be underestimated by a lack of general 
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awareness of AAT deficiency as well as diagnostic strategies 
omitting whole gene sequencing.
Interestingly, in the present case, the mutation was found 
in the homozygous form, pointing toward a hereditary mecha-
nism. It is possible that this mutation has a local prevalence in 
the patients’ region of origin (Kayseri, Turkey), but this has 
not been investigated. A new spontaneous mutation involving 
the same insertion in both alleles seems unlikely.







,3 resulting in unde-
tectable AAT messenger RNA and severe AAT deficiency 





 had severe COPD in their forties19 and 
carriers of Q0
granite falls
 had severe emphysema.3
The possibility of AAT augmentation with intravenous 
AAT therapy for long-term treatment was discussed with 
the patient. The indication for therapy in Germany is severe 
AAT deficiency (,80 mg/dL) and FEV
1
 between 35% and 
60%, but this may vary in different countries. Augmentation 
therapy has been shown to reduce the progression of emphy-
sema, as assessed by computed tomographic densitometry.20 
Effectiveness in slowing the decline in lung function has been 
suggested by a meta-analysis including controlled and uncon-
trolled trial data.21 A few reports have suggested positive 
effects of augmentation therapy on airway inflammation,22,23 
but the effects on bronchiectasis have not been conclusively 
studied. Given the limited evidence for augmentation treat-
ment in cases such as the one described, we favor treatment 
only within the setting of a clinical study. Furthermore, 
genetic testing was advised for the patient’s children.
Conclusion
We describe a novel SERPINA-1 mutation associated with 
severe AAT deficiency. The atypical presentation of the 
patient with severe cystic bronchiectasis highlights AAT 
deficiency as a differential diagnosis in bronchiectasis. 
Awareness should be raised as to a possible increased risk of 
thromboembolism associated with AAT deficiency. Further 
studies are necessary to investigate the risk of thrombosis as 
well as the effectiveness of augmentation therapy in AAT 
deficiency-associated bronchiectasis.
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